Summary MDM2 is an oncoprotein that inhibits p53 tumour-suppressor protein. Amplification of the MDM2 gene and overexpression of its protein have been observed in some human malignancies, and these abnormalities have a role in tumorigenesis through inactivation of p53 function. To determine the clinicopathological and prognostic value of MDM2 abnormalities in non-small-cell lung cancer (NSCLC), MDM2 gene amplification and its protein expression status were analysed in surgically resected materials. MDM2 gene amplification was detected in only 2 (7%) of the 30 tested patients. MDM2 protein was found immunohistochemically in a total of 48 (24%) of the 201 patients. MDM2 protein was slightly frequently observed in patients with adenocarcinoma, but its presence or absence was not associated with clinicopathological factors such as T-factor, N-factor, stage, tumour size, differentiation or p53 protein status. Overall, MDM2-positive patients tended to have a better prognosis (P = 0.062). In particular, among immunohistochemically p53-negative patients (n = 110), those with positive MDM2 protein expression showed significantly better prognosis (P = 0.039) and, in a multivariate analysis, MDM2 protein status was a favourable prognostic factor (P = 0.037). In contrast, among p53-positive patients (n = 91), there was no difference in prognosis depending on MDM2 protein status. Thus, in the NSCLC patients studied, MDM2 gene amplification was a minor event, but expression of its protein, which was often observed immunohistochemically, was a favourable prognostic marker, especially among patients without p53 protein accumulation. Further study is needed to determine how MDM2 protein expression results in a better prognosis.
The MDM2 gene was originally identified and cloned by amplification in a transformed tumorigenic Balb/c 3T3 fibroblast cell line (Cahilly-Snyder et al, 1987; Fakharzadeh et al, 1991; Oliner et al, 1992) . Its product, p90, is now considered to form a tight complex with both the wild-type and mutant p53 tumour-suppressor gene protein and to inactivate wild-type p53 function by masking the Nterminal acidic transactivating domain of p53 protein, indicating that abnormalities of the MDM2 gene may be closely associated with tumorigenesis and/or tumour development (Olson et al, 1993; Haines et al, 1994) . Indeed, MDM2 gene amplification and overexpression of its product have been described in several types of malignancies in humans. However, the clinicopathological role of these abnormalities has yet to be determined.
In lung cancer, p53 abnormalities have been well examined but, to our knowledge, MDM2 abnormalities in this disease have been reported only by Marchetti et al (1995a) . However, because of the relatively small number of samples tested in their study, its clinicopathological and prognostic significance is as yet unknown. Hence, because p53 abnormalities in this disease may be essential for biological and clinical characteristics of the tumour, we examined MDM2 abnormality status, especially in those patients without p53 abnormalities. MDM2 gene amplification and its protein expression were examined in a series of surgically resected non-small-cell lung cancer (NSCLC) cases in association with clinicopathological parameters, p53 protein accumulation and prognosis. the international TNM staging system (Mountain, 1986) 
MATERIALS AND METHODS

MDM2 amplification and p53 mutation analysis
Southern blot analysis was performed to detect amplification of the MDM2 gene, as described previously (Takami et al, 1994) . The human MDM2 cDNA clone (c14-2; nt 1-949), which was kindly provided by Drs B Vogelstein and KW Kinzler, was used as a hybridization probe. pYNH 132 on chromosome 6p, pLYNZ9. 1 on chromosome 2p and pMCA I -I on chromosome 15q were used as internal diploid standards (kindly provided by Dr Y Nakamura). Briefly, 5 .tg of high molecular weight DNA derived from tumour tissues was digested with EcoR I and then electrophoresed on 0.8% agarose gel followed by transfer to a nylon filter. The DNAs on the filters were sequentially hybridized with the MDM2 gene probe, c 14-2, and three control probes, pYNH 132, pLYNZ9. 1 and pMCA I -1. The intensity of the hybridization signals was measured by densitometry. The relative signal intensities of the MDM2 gene were calculated by comparing the ratio of MDM2 to three control probes and, when the samples showed a more than two fold increase in signal intensity of MDM2, they were hybridized with two probes, pYNH15 on chromosome 12q and pHua2M9 on chromosome 12p, to determine whether or not the increase was due to non-specific polysomies of the chromosome. Mutations of the p53 gene were examined using fluorescencebased polymerase chain reaction single-strand conformation polymorphism (PCR-FSSCP), as described previously by Katsuragi et al ( 1995) . This technique was used for the detection of point mutations in the p53 gene in exons 5, 6, 7 and 8 by an automated DNA sequencer and software.
Immunohistochemical analysis
Sections were cut at 4 ,um, dewaxed and rehydrated through a graded ethanol series. Before staining, sections were pretreated with microwave irradiation for antigen retrieval, as described previously (Cattoretti et al, 1992; Marchetti et al, 1995b; McCann et al, 1995; Ofner et al, 1995) . Incubation with the primary antibodies (monoclonal MDM2 antibody, IF-2, Oncogene Science, USA, and monoclonal p53 antibody, DO-7, Novocastra Laboratories, UK), British Journal of Cancer (1997) 75(9), [1302] [1303] [1304] [1305] [1306] [1307] [1308] . Cancer Research Campaign 1997 the enzyme colour reaction, haematoxylin counterstaining and mounting were carried out as described elsewhere (Foulkes et al, 1995; Marchetti et al, 1995a and b; McCann et al, 1995; Ofner et al, 1995; Matsumura et al, 1996) . Immunostaining results were assessed, taking into account the cancer cells whose nuclei showed positive immunoreactivity for MDM2 ( Figure 1 ) or p53 protein. The percentage of immunoreactive nuclei was evaluated by scanning the whole section at medium and high magnification and by counting at least 500 cells in the most densely stained tumour areas. The patients were classified into three groups: a strongly positive group (++), with more than 50% positive cancer cells in the tissue; a weakly positive group (+), with 10-50% positive cancer cells; and a negative group (-) with less than 10% or no positive cancer cells (McCann et al, 1995) .
Statistical analysis
The chi-square test was applied for statistical analysis. For survival data, statistical significance was analysed using the logrank test. Variables related to survival were analysed using Cox's proportional hazards regression model with SAS software (Statistical Analysis Institute, Cary, NC, USA). P < 0.05 was considered to be significant and 0.05 < P < 0.10 was considered to be marginally significant. (-vs + vs ++) , there is no statistical difference in post-operative survival curves (P= 0.163), but MDM2-positive patients, including those with strong (++) and weak (+) expression, show marginally better prognosis than MDM2-negative patients (P = 0.062) 
Post-operative prognosis
Decending on MDM2 protein expression status, post-operative overall survival was analysed for 201 patients (Figure 3) . Overall, there was no statistically significant difference in prognosis among the three groups (P = 0.163), but MDM2-positive patients, including those strongly and weakly positive, showed slightly better prognosis than MDM2-negative patients (P = 0.062). In addition to MDM-2 protein status, T-factor, N-factor, stage, tumour size and differentiation were also significantly or marginally significantly associated with prognosis (Table 3 ). p53 protein status showed no influence on prognosis in the present series.
Considering a biophysiological function of MDM2 and p53 proteins (Olson et al, 1993; Haines et al, 1994) , survival was separately analysed according to p53 protein status. In the p53-negative group (110 patients), MDM2-positive patients, including those strongly and weakly positive, showed a significantly more favourable prognosis than MDM2-negative patients ( Figure 4A , P = 0.039). In particular, even among the p53-negative group with stage I disease (64 patients), a similar result was obtained ( Figure  4B , P = 0.049). In a multivariate analysis of the p53-negative group (Table 4) , the P-value of MDM2 protein expression was significant for survival (P = 0.037), in addition to N-factor. However, among the p53-positive group (91 patients), there was no difference in the post-operative survival curve with the MDM2 protein status ( Figure 4C , P = 0.556).
British Joumal of Cancer (1997) 75(9) Days after operation Figure 4 Post-operative survival curves according to MDM2 protein expression among p53-negative group (A), p53-negative group with stage disease (B) and among p53-positive group (C). In the p53-negative group (110 patients), the MDM2-positive patients (++ and +) showed significantly more favourable prognosis than the MDM2-negative patients (A, P = 0.039), even in the p53-negative group with stage disease (64 patients) (B, P = 0.049). In contrast, in the p53-positive group (91 patients), there was no difference in post-operative survival curves (C, P = 0.556) DISCUSSION MDM2 gene amplification has been described in several types of human sarcomas (Leach et al, 1993; Florenes et al, 1994; BuesoRamos et al, 1995; Nakayama et al, 1995) , including 15-36% of soft tissue sarcomas and 10-15% of osteosarcomas. Similarly, this amplification has been detected in 8-10% of brain tumours (Reifenberger et al, 1993) . MDM2 gene amplification has also been reported in human cancers, such as breast cancer, in which its incidence is 4-13% of the primary tumours (Marchetti et al, 1995b; McCann et al, 1995) , and oesophageal cancer, in which the incidence is as high as 18% (Shibagaki et al, 1995) ; but overall in other cancers, including urinary bladder tumours (Lianes et al, 1994) , cervical cancers (Kessis et al, 1993; Ikenberg et al, 1995) , head and neck tumours (Waber et al, 1993) , some paediatric tumours (Waber et al, 1993) and urothelial cancers (Habuchi et al, 1994) , this event is now considered to be rather infrequent. In the NSCLC cases studied here, its incidence was only 7% (2 of 30 patients tested), compatible with that (6%) reported by Marchetti et al (1995a) , and, in addition, its amplification grade was relatively low (5.5-fold and 2.7-fold) in comparison with the other tumours, indicating that amplification of this oncogene in this disease may also be a relatively infrequent event through tumorigenesis and tumour development. Interestingly, Marchetti et al (1995a) emphasized that MDM2 gene amplification was observed only in patients with adenocarcinoma but, in the present study, one patient with squamous cell carcinoma showed MDM2 gene amplification.
In immunohistochemical studies using monoclonal anti-MDM2 protein antibody, the incidence of MDM2 immunohistochemical (over)expression in human cancers has been reported to be 30% in bladder cancers (Lianes et al, 1994) , 20% in colorectal cancers (Ofner et al, 1995) , 3% in ovarian cancers (Foulkes et al, 1995) , 40% in oral carcinoma (Matsumura et al, 1996) and 22-41% in breast cancers (Marchetti et al, 1995b; McCann et al, 1995) . In NSCLC, whereas Marchetti et al (1995a) reported that MDM2 oncogene product expression was detected immunohistochemically only in three (6%) patients with gene amplification, it was detected in the present study in 24% of patients, independently of MDM2 gene amplification status. This difference in incidence reported between Marchetti et al (1995a) and ourselves is probably caused by the use of frozen sections in the former study, whereas paraffin sections, possibly larger in size, were used in the present study. In addition, the criteria for the positivity of immunostaining may have been another related factor. Thus, when considering together our findings on NSCLC, we believe that its expression (in contrast to its gene amplification) is not a rare, but a more common, event in human cancer tissues.
Although Marchetti et al (1995a) In the present study, there was no significant association between MDM2 expression and tumour-staged parameters (Table  2 ) and, even in regard to MDM2 gene amplification, one case was in stage I and another in stage IIIA. There was also no such association in the three patients with positive amplification and overexpression described by Marchetti et al (1995a) . In addition, MDM2 protein status did not appear to be associated with p53 protein accumulation status (Table 2) abnormalities in NSCLC may be not so simple. However, only in the two patients with MDM2 amplification, no p53 gene mutation was detected in spite of strongly positive p53 protein accumulation; this observation is compatible with that of Marchetti et al (1995a) . Considering that the antibody recognizes both the wildtype and the mutant forms of p53 protein, it is possible that immunohistochemically detected protein in such patients is wildtype p53, which may be stabilized and accumulated by MDM2 protein expression (Keleti et al, 1996) .
The prognostic value of MDM2 protein expression is observed only among p53-negative patients, but not among p53-positive patients. The observation that MDM2-positive patients showed marginally better prognosis than MDM2-negative patients, on the whole, reflects the findings among p53-negative patients. Thus, it is concluded that MDM2 protein status is a useful prognostic marker only in such patients. Considering a biophysiological function of MDM2 and p53 proteins (Olson et al, 1993; Haines et al, 1994) , mutant-type p53 itself may have lost its p53 function, leading to the speculation that MDM2 abnormalities have little or no effect on the p53-mediated pathway. The findings observed among p53-positive patients in this study support this hypothesis. In contrast, we had hypothesized that MDM2 abnormalities are an alternative mechanism, escaping from p53-regulated growth control in wild-type p53 tumours in the same fashion as in mutantp53 tumours, but the present findings obtained in NSCLCs appear to be rather paradoxical.
The reason for the present clinical outcome among the p53-negative patients is unknown. In this respect, it was recently reported that the MDM2 gene encodes a number of alternatively spliced mRNAs that give rise to proteins ranging in size from 40 kDa to 90 kDa. Several investigators have described not only a p90 protein, the original form, but also the representative forms, p57-58, p74, p76 and p85 proteins as the MDM2 gene products in various types of tumours (Olson et al, 1993; Haines et al, 1994; Landers et al, 1994; Bueso-Ramos et al, 1995; Gudas et al, 1995) . In particular, it is noteworthy that the variant forms p74 and p76, lacking the N-terminal protein domain of p90 protein, do not inhibit p53 protein (Olson et al, 1993; Haines et al, 1994) . The antibody IF2, used in the present study, enables detection of such forms as p90, p74, p76 and p57-58 Gudas et al, 1995) . Therefore, some immunohistochemically detected MDM2-positive patients may have been included as showing a different function of variant MDM2 protein, e.g. p74 or p75, from the original MDM2 protein, p90. Secondly, p53 abnormalities examined by immunohistochemistry are not always consistent with those examined by analysis of its gene. In fact, several patients even with strongly positive p53 accumulation showed no p53 mutation by the PCR-FSSCP method (Table 1 ). Conversely, it is possible that some p53-negative patients may have been included as those with some p53 abnormalities at the gene level. The present prognostic analysis was firmly based on immunohistochemistry for tumour phenotype and, therefore, further study is needed to elucidate the mechanism underlying the apparently contradictory effects of MDM2 protein on prognosis.
In other tumours, the prognostic value of MDM2 abnormalities remains controversial. In breast cancers, MDM2 overexpression is strongly associated with oestrogen receptor expression, suggesting that MDM2 expression status may also be a favourable prognostic factor (Sheikh et al, 1993; Takami et al, 1994; Marchetti et al, 1995b; McCann et al, 1995; Gudas et al, 1995) . In bladder cancer, Lianes et al (1994) reported that MDM2 overexpression was observed in patients with relatively early-staged and low-grade tumours, suggesting that MDM2 overexpression may be an early event or possibly a favourable factor associated with low-grade malignancy, although there have been no reports clearly describing its association with prognosis. On the other hand, in oesophageal cancer, MDM2 gene amplification has been described as being a rather unfavourable prognostic factor (Schibagaki et al, 1995) . MDM2 overexpression in leukaemias also appears to be associated with unfavourable chromosomal abnormalities (Bueso-Ramos et al, 1993) . Thus, the influence of MDM2 gene abnormalities on tumour malignancy may appear to be different when studied with tumour tissues. Further study is needed considering p53 abnormalities in these tumours to determine the prognostic value of MDM2 abnormalities.
